Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Analysis of plasma circulating tumor DNA in borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant modified FOLFIRINOX: Clinical relevance of DNA damage repair gene alterations.
Authors
Dong-Hoon Lim
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;
Dong-Hoon Lim , Jaewon Hyung , Sang Soo Lee , Jae Ho Jeong , Baek-Yeol Ryoo , Kyu-Pyo Kim , Changhoon Yoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 737)
DOI
10.1200/JCO.2023.41.4_suppl.737
Abstract #
737
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
First Author: Amit Jethanandani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association between TP53 gain of function and loss of function mutational subgroups and survival in pancreatic adenocarcinoma.
First Author: Nitzan Zohar
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers